ProTgen logo
ProTgen logo

ProTgen

protgen.bio
protgen.bio • Likely startup • New
Likely startup • New
Actively hiring
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Backers
1
FACIT
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
FACIT fund
Investors in similar startupsfunds that back the companies most like this one
Canaan
backs Greywolf Therapeutics, Draig Therapeutics
Y Combinator
backs SFA Therapeutics
Andreessen Horowitz
backs Ardatx
Newfund
backs ORIA Bioscience | Isolated Organelles for Drug Discovery
Refactor Capital
backs Onyx Bio
SR One
backs Draig Therapeutics
Similar startupsby what they do, their industry and backers
ORIA Bioscience | Isolated Organelles for Drug DiscoveryFounded 2022
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
Block Biosciences11-50 employees
At Block Biosciences, we are developing first-in-class therapeutics designed to intercept the spread of cancer to the brain.
Greywolf TherapeuticsFounded 2017 • 501-1000 employees
Novel antigen modulation technology that controls T cells to guide the immune system.
NephroDI Therapeutics1-10 employees
About Us NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes…
Draig TherapeuticsFounded 2024 • 501-1000 employees
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
Onyx BioVenture round $8M · 7 mo ago • Founded 2021 • 11-50 employees
Onyx is a research collective of citizens and scientists building a virtual cell to better understand the immune system.

Overview

ProTgen develops first-in-class targeted Notch activators that generate progenitor T cells to restore thymic function and immune competence.